Company intelligence / Profile preview

TheraPPI Bioscience

Lyon, Auvergne-Rhône-Alpes, Francetppibio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

TheraPPI is a preclinical-stage biotech developing small molecule drugs that modulate novel protein-protein interactions within the RAS-MAPK pathway. Their lead programs aim to overcome cancer resistance and improve outcomes for advanced cancers and rare diseases. The company has received recognition such as the French Tech Seed label for its innovation.

Therapeutic areas: ImmunologyOncologyRare Diseases
Modalities: Small molecules targeting protein-protein interactions (PPIs)
Industry: Biotech

Drug pipeline

1 asset

TheraPPI Bioscience-novel protein–protein interaction in the RAS–MAPK pathway

Preclinical

Partnerships

Collaborations with academic institutions including CRCL (Université Claude Bernard Lyon I, Inserm, Centre Léon Bérard, CNRS) and C3D technology platform of Lyon.

Beyond the preview

Go deeper on TheraPPI Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraPPI Bioscience.

Explore the full profile